Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention
- Conditions
- HIV InfectionsSexually Transmitted Diseases
- Interventions
- Device: Dot DiaryOther: PrEPmate
- Registration Number
- NCT04855773
- Lead Sponsor
- Public Health Foundation Enterprises, Inc.
- Brief Summary
The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prevent HIV infection.
- Detailed Description
This is a clinic-based, multi-site, randomized, two-arm study to compare the effectiveness of two mobile technologies designed to support PrEP adherence and continuation in cisgender and transgender men who have sex with men (MSM) and transgender women (TGW). All study participants will receive PrEP per standard of care at each of the study sites.
Participants randomized to PrEPmate will receive an interactive bidirectional text-messaging intervention that supports PrEP use through personalized communication between patients and providers. Key components include (1) weekly short message service (SMS) check-ins and a bidirectional SMS messaging platform; (2) customized daily SMS pill-taking reminders; (3) link to online PrEP Basics and videos and testimonials.
Participants randomized to Dot Diary will receive a mobile app that promotes self-management of PrEP use and sexual health. Key components include (1) a digital pill-taking and sexual diary, with pill-taking reminders; (2) sex-positive badges earned via app use; and (3) real-time feedback on protection levels afforded by PrEP. Each participant will be followed for approximately 12 months. Staff at the participating clinics will also participate in in-depth interviews to give feedback on implementation challenges and experiences in the clinic-setting, and experience working with patients using the mobile technologies.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
-
Self-identifies as a cisgender man, transgender man (assigned female at birth, trans-masculine spectrum), or transgender woman (assigned male sex at birth, trans-feminine spectrum)
-
Report sex with a cisgender man or transgender woman or any individual assigned male sex at birth in the past 12 months
-
Age 15 years or older
-
Willing and able to provide written informed consent
-
Owns an iOS or Android mobile phone and able to access the internet and send and receive text messages
-
Able to understand, read, and speak English or Spanish
-
Newly initiated PrEP or currently on PrEP and at risk for PrEP discontinuation based on at least one of the following:
- Initiated PrEP within the past 6 months, or
- Has any of the following risk factors for PrEP discontinuation: missed clinic visits; age < 30; African-American or Latino; transgender gender identity; or self-reported illicit substance use
- Currently enrolled in another PrEP intervention study
- Unable to complete 12 month study participation
- Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dot Diary mobile application Dot Diary Participants randomized to this study arm will download and use the Dot Diary mobile application on a personal device, to support PrEP adherence and continuation. PrEPmate PrEPmate Participants randomized to this study arm will receive the PrEPmate mHealth intervention (bi-directional text messaging with PrEP navigators/clinic staff) to support PrEP adherence and continuation.
- Primary Outcome Measures
Name Time Method PrEP adherence as measured by tenofovir diphosphate levels in dried blood spots DBS measured through 12 months PrEP adherence will be measured by tenofovir diphosphate (TFV-DP) levels in dried blood spots (DBS). Adequate adherence will be defined as having a TFV-DP ≥ 700 femtomoles/punch in DBS for daily PrEP users, which has been associated with high levels of protection in prior PrEP trials.
Satisfaction with medical care Satisfaction measured through 12 months Satisfaction with medical care will be measured by the Consumer Assessment of Health Care Processes and Services (CAHPS), a critical tool for evaluating patient satisfaction and patient-centeredness of care
Patient engagement Patient engagement measured through 12 months Patient engagement will be measured by the short-version Patient Activation Measure (PAM).
- Secondary Outcome Measures
Name Time Method PrEP continuation based on medication refills PrEP continuation measured through 12 months PrEP discontinuation will be defined as having a PrEP interruption of ≥30 days based on medication refill dates using blinded outcome ascertainment of electronic medical and pharmacy refill records.
Sexual satisfaction Sexual satisfaction measured through 12 months Sexual satisfaction will be measured by the New Sexual Satisfaction Scale Short Version (NSSS-S), a validated 12-item questionnaire in which patients score their sexual satisfaction on five dimensions (sexual sensations, sexual presence/awareness, sexual exchange, emotional connection/closeness, and sexual activity)
Adherence self-efficacy Adherence self-efficacy measured through 12 months Patient-reported adherence self-efficacy will be measured by the self-efficacy scale for PrEP use, which has been validated for PrEP use
Trial Locations
- Locations (4)
University of Miami
🇺🇸Miami, Florida, United States
San Francisco AIDS Foundation
🇺🇸San Francisco, California, United States
Bridge HIV, San Francisco Department of Public Health
🇺🇸San Francisco, California, United States
Whitman-Walker Health
🇺🇸Washington, District of Columbia, United States